Market closed

Inhibikase Therapeutics Inc./$IKT

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.

Ticker

$IKT
Trading on

Industry

Biotechnology

Employees

16

IKT Metrics

BasicAdvanced
$147M
-
-$1.16
1.02
-
$147M
1.02
$2.58
$1.91
26.369
26.126
0.116
-31.60%
-52.00%
1.44
1.44
-2.446
-63.23%
-38.01%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $IKT

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs

What’s the current market cap for Inhibikase Therapeutics Inc. stock?

Inhibikase Therapeutics Inc. (IKT) has a market cap of $147M as of April 05, 2025.

What is the P/E ratio for Inhibikase Therapeutics Inc. stock?

The price to earnings (P/E) ratio for Inhibikase Therapeutics Inc. (IKT) stock is 0 as of April 05, 2025.

Does Inhibikase Therapeutics Inc. stock pay dividends?

No, Inhibikase Therapeutics Inc. (IKT) stock does not pay dividends to its shareholders as of April 05, 2025.

When is the next Inhibikase Therapeutics Inc. dividend payment date?

Inhibikase Therapeutics Inc. (IKT) stock does not pay dividends to its shareholders.

What is the beta indicator for Inhibikase Therapeutics Inc.?

Inhibikase Therapeutics Inc. (IKT) has a beta rating of 1.02. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.